Mar 2018

AXXAM expands its natural products service business

Thursday 22nd March 2018, Milan - Axxam SpA (“AXXAM”) announces today the acquisition of all shares of IMAX Discovery GmbH (“IMAX Discovery”) held by IMD Natural Solutions GmbH (“INS”) to make IMAX Discovery a subsidiary of AXXAM. In the course of this transaction, IMAX Discovery acquired the natural products libraries of INS.

With this acquisition and through IMAX Discovery, AXXAM has expanded its discovery services portfolio to the food & beverage industry and emphasizes its commitment to building its service business with unique offerings in natural product innovation as well as flavor solutions. As a consequence, AXXAM will also transfer its service business within the fragrance field into IMAX Discovery.

Open PDF document

Jan 2018

Axxam and Proximagen enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain and inflammation

January 10th 2018 - Milan (Italy) and Cambridge (UK) - Axxam S.p.A. and Proximagen Ltd. today announced a strategic drug discovery collaboration for the identification and optimisation of small molecules as potential therapeutics in the fields of neuroscience, pain and inflammation.

Over the course of the collaboration, Axxam and Proximagen scientists will collaborate to identify novel molecules modulating validated and promising biological targets of therapeutic interest for a range of disorders requiring novel therapeutic approaches. Starting from assay development and high throughput screening campaigns, using the Axxam AXXDIV3.0 library, the subsequent hits will be progressed through optimisation at Proximagen.

This collaboration is the latest evolution of an existing relationship between the two companies.

Open PDF document

Jan 2018

Rewind Therapeutics, founded by Axxam and CD3, focusing on myelin-related diseases, raises €15.2 million in Series A Financing Round

January 4th, 2018 - Milan (Italy) - Axxam is proud to announce that Rewind Therapeutics, a Belgian biotech company recently founded by Axxam itself and KU Leuven’s Centre for Drug Design and Discovery (CD3 - Leuven, Belgium), has completed a €15.2 million Series A round that will finance research programs directed towards the development of novel re-myelinating therapies for patients suffering from Multiple Sclerosis and other myelin-related diseases. The round was led by life science investors Boehringer Ingelheim Venture Fund (BIVF), Merck Ventures BV (MV) and Participatiemaatschappij Vlaanderen (PMV), together with CD3 and KU Leuven Gemma Frisius Fonds (GFF).  For more info please open the Press Release from Rewind Therapeutics.

Open PDF document